These programs, named ATK and DELIS, come from renowned public research laboratories in  France.

ATK and DELIS programs have generated NCE that open up a therapeutic pathway for neurodegenerative pathologies without any therapeutic solution to date:

• DISEASES TARGETED:
  Neurodegenerative diseases, especially:
  - Alzheimer's disease
  - Huntington's disease (ATK)
  - ALS et CIAS (DELIS)
   
• MECHANISM OF ACTION:
  - ATK > TrkB PAM (Positive Allosteric Modulator) / first in class
  - DELIS > agoniste sigma1 / best in class potential
   
• STATUS:
  - hit to lead opportunity (SAR and first optimization round)
  - in vitro caracterization ADME/TOX
  - PK et in vivo tox profile
  - in vivo POC

ARE YOU A STARTUP, A BIOTECH COMPANY OR A BIG PHARMA ? 

YOU CAN :

• take a licence for both molecules or only one
• benefit from an exclusive and worlwide exploitation rights
• connect and collaborate directly with the researchers-inventors, experts in the targets
   

IN ADDITION!
The licensing process of these technologies will be fully managed by SATT CONECTUS (French TTO). You will have a single point of contact throughout the transfer process.